Palatin Technologies (PTN) Long-Term Deferred Tax (2015 - 2025)
Palatin Technologies' (PTN) quarterly Long-Term Deferred Tax came in at $46.1 million in Q2 2025, down 26.56% YoY from $62.7 million in Q2 2024, and down 26.56% on a QoQ basis from $62.7 million in Q2 2024.
Palatin Technologies (PTN) Long-Term Deferred Tax (2015 - 2025) Analysis & Trends
Palatin Technologies (PTN) has 10 years of Long-Term Deferred Tax data on file, last reported at $46.1 million in Q2 2025.
- Quarterly Long-Term Deferred Tax fell 26.56% year-over-year to $46.1 million in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $46.1 million (down 26.56% YoY) and the FY2025 annual result came in at $46.1 million, down 26.56% from the prior year.
- Long-Term Deferred Tax slipped to $46.1 million in Q2 2025, from $62.7 million in the prior quarter.
- In the past five years, Long-Term Deferred Tax ranged from a high of $62.7 million in Q2 2024 to a low of $32.2 million in Q2 2021.
- A 4-year average of $44.1 million and a median of $40.7 million in 2022 frame the typical range for Long-Term Deferred Tax.
- Annual changes were most pronounced in 2022 — Long-Term Deferred Tax rose 9.83% — and 2025, when it slipped 26.56%.
- Tracing PTN's Long-Term Deferred Tax over 4 years: stood at $32.2 million in 2021, then increased by 9.83% to $35.3 million in 2022, then jumped by 77.49% to $62.7 million in 2024, then slipped by 26.56% to $46.1 million in 2025.
- The last three Long-Term Deferred Tax figures came in at $46.1 million (Q2 2025), $62.7 million (Q2 2024), and $35.3 million (Q2 2022), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Palatin Technologies | 40.37 Mn | 40.37 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 46.05 Mn |
| Jun 30, 2024 | 62.71 Mn |
| Jun 30, 2022 | 35.33 Mn |
| Jun 30, 2021 | 32.17 Mn |
| Jun 30, 2020 | 32.42 Mn |
| Jun 30, 2019 | 26.59 Mn |
| Jun 30, 2018 | 29.50 Mn |
| Sep 30, 2017 | 274,745.00 |
| Jun 30, 2016 | 125.54 Mn |
| Jun 30, 2015 | 102.90 Mn |